Adjuvant immunotherapy reduces relapse risk in resected or ablated hepatocellular cancer
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed
Advanced pancreatic cancer: is triple chemotherapy into question?
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Triplet therapy does not outperform doublet treatment first line in metastatic pancreatic cancer
Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting
New treatment paradigms may offer advances in pancreatic cancer treatments
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
Data are still insufficient to recommend immune checkpoint inhibitors in perioperative therapy for gastric/gastro-oesophageal junction cancers
The impact of immunotherapy on disease progression and survival remains uncertain, but biomarker selection may be the future